KOSPIBiotech & Pharma005690

Pharmicell

₩8,250▲ 2.48%2026-11-18 close
Market Cap
₩495B
Turnover
₩3.6B
Volume
440K
Shares out.
60M
PER
11.6×
PBR
3.5×
EPS
₩767
Dividend Yield
0.56%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩50 per share · Prices as of the 2026-11-18 close

01

Report overview

Electronic Materials Drive Pharmicell's Earnings Recovery

Pharmicell's annual results rose sharply from the 2023 low through 2025, and cumulative results for the first three quarters of 2026 kept growing year on year, but quarterly net income attributable to controlling shareholders has declined for three consecutive quarters since the fourth quarter of 2025.

  1. 1

    Full-year 2025 revenue reached KRW 114.1 billion and operating profit reached KRW 34.3 billion, the largest year in the 2022 to 2025 period. Both figures rose in 2024 and 2025 after the 2023 low.

  2. 2

    According to the company announcement on November 12, 2026, cumulative revenue for the first three quarters of 2026 was KRW 1.126 billion, up about 42% year on year, and operating profit was KRW 382 million, up about 55%. Electronic materials and pharmaceutical raw materials such as nucleosides led the growth.

  3. 3

    Net income attributable to controlling shareholders peaked at KRW 15.7 billion in the fourth quarter of 2025 and has declined for three consecutive quarters through the third quarter of 2026. The sum over the last four quarters is KRW 46 billion.

  4. 4

    The biochemical division drives results, while the biomedical division remains small, with cumulative third-quarter 2026 revenue of KRW 2.6 billion. The portfolio is concentrated in one division.

  5. 5

    The third plant in Ulsan is under construction with a target completion at the end of January 2027, and the company plans to expand production capacity after completion. Whether capacity expands after that date is the next checkpoint.

02

Business structure

Pharmicell operates two divisions, biochemical and biomedical. The biochemical division produces pharmaceutical raw materials such as nucleosides and mPEG, as well as low-dielectric electronic materials used in advanced IT infrastructure.

In the first three quarters of 2025, biochemical division revenue was KRW 77.5 billion and biomedical division revenue was KRW 1.9 billion. Low-dielectric electronic materials accounted for KRW 43.2 billion, or 54% of total revenue, up 181.7% from KRW 15.3 billion a year earlier.

These materials are used in copper-clad laminates, which are applied in AI accelerators. Nucleosides serve as raw material for RNA-based nucleic acid therapeutics, and demand is supported by the expansion of mRNA vaccines and gene therapies.

Pharmaceutical raw material sales grew as global supply to overseas customers expanded. First-half 2026 results were likewise led by electronic materials and nucleosides and mPEG.

The biomedical division covers stem cell therapies, cosmetics, contract manufacturing (CMO) and contract testing, and its cumulative revenue for the first three quarters of 2026 was KRW 2.6 billion, up about 39% year on year. The company says it aims to improve this division through expansion of its CMO business.

Competition can be viewed as a contest among materials suppliers in which customer qualification and production capacity are the key factors.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩25.6B₩8.1B31.7%
2025Q4₩34.6B₩9.6B27.8%
2026Q1₩36.7B₩13.1B35.6%
2026Q2₩39B₩13.2B33.9%
2026Q3₩37B₩11.9B32.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩60.2B₩8.9B₩10.9B14.7%13.7%41.4%
2023₩56.2B₩1.3B₩3.6B2.3%4.5%15.1%
2024₩64.9B₩4.7B₩6.3B7.2%7.3%14.8%
2025₩114.1B₩34.3B₩40.3B30.1%32.5%26.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

Revenue on a disclosed basis fell from KRW 60.2 billion in 2022 to KRW 56.2 billion in 2023, a 6.6% decline, then rose to KRW 64.9 billion in 2024, up 15.3%, and to KRW 114.1 billion in 2025, up 75.9%. 2025 was the largest year of the 2022 to 2025 period.

Operating profit fell from KRW 8.87 billion in 2022 to KRW 1.3 billion in 2023, down 85.4%, then rose 259.2% to KRW 4.66 billion in 2024 and 636.8% to KRW 34.3 billion in 2025. Operating margin was 14.7% in 2022, 2.3% in 2023, 7.2% in 2024 and 30.1% in 2025. In 2025, operating profit growth far exceeded revenue growth.

The company attributes growth to electronic materials and raw materials such as nucleosides and mPEG. Net income attributable to controlling shareholders was KRW 10.9 billion in 2022, KRW 3.58 billion in 2023 (down 67.1%), KRW 6.33 billion in 2024 (up 77.0%) and KRW 40.3 billion in 2025 (up 536.3%).

In every year in the table, net income including non-controlling interests matches the figure attributable to controlling shareholders.

On a quarterly basis, revenue rose from KRW 25.6 billion in the third quarter of 2025 to KRW 34.6 billion in the fourth quarter, up 35.0% from the prior quarter, with operating profit of KRW 9.62 billion. Revenue was KRW 36.7 billion in the first quarter of 2026 and KRW 39 billion in the second quarter.

The third quarter of 2026 recorded revenue of KRW 37 billion, down 5.2% from the prior quarter, and operating profit of KRW 11.9 billion, down 9.8%. Operating cash flow was KRW 7.91 billion in 2022, KRW 12.9 billion in 2023, KRW 3.5 billion in 2024 and KRW 41.1 billion in 2025.

The debt ratio was 26.9% at the end of 2025, down from 41.4% in 2022. Total equity at the end of 2025 was KRW 123.9 billion, and total liabilities were KRW 33.3 billion.

05

Industry analysis

Pharmicell's results are closely tied to AI infrastructure investment. Low-dielectric electronic materials are used in copper-clad laminates, which are applied in AI accelerators and 5G network equipment. The company said demand for low-dielectric materials is rising as global companies continue to build data centers.

This demand moves with the data center investment cycle, so slower investment could affect revenue growth. Demand for nucleosides is linked to the expansion of the mRNA vaccine and gene therapy markets.

The pace of growth in those markets depends on clinical and approval timelines, so the direction of raw material demand should be read together with therapeutic development. On competition, Pharmicell is a materials supplier inside qualified supply chains, which is a distinguishing feature.

In the bio CDMO segment, large and mid-sized companies compete, but Pharmicell's core lines are raw materials and electronic materials, so direct comparison with CDMO peers is limited. In terms of the cycle, Pharmicell sits in a phase of steep demand growth for electronic materials. How long that growth lasts depends on the trajectory of AI equipment investment.

06

Outlook

In its announcement of third-quarter 2026 results, the company said it will strengthen its core business and expand its bio CMO business to improve results in the biomedical division. The third Ulsan plant is under construction to meet rising demand for advanced AI materials and pharmaceutical raw materials.

The target completion date is the end of January 2027, and the company plans to expand production capacity after completion. Added capacity could raise supply of electronic materials and raw materials, but whether initial utilization and customer volumes turn into revenue is the key question.

Cumulative revenue for the first three quarters of 2026 reached KRW 112.6 billion, close to full-year 2025 revenue of KRW 114.1 billion. Whether full-year 2026 revenue exceeds the 2025 level is therefore the next checkpoint.

Results for the fourth quarter and full year 2026 are expected in early 2027, and the annual report is due by the end of March 2027. It is also worth watching whether fourth-quarter net income attributable to controlling shareholders breaks the three-quarter decline. In the biomedical division, CMO contract wins and sales trends in the cosmetics line are the items to track.

07

Valuation

PER
11.6×
PBR
3.5×
ROE
35.1%
EPS
₩767
BPS
₩2,530
Dividend per share
₩50

The current share price tells two different stories depending on whether earnings or book value is the anchor. Because earnings rose sharply in 2025 on a disclosed basis, multiples on earnings can be read as reflecting a recovered earnings base, unlike the period when profit was small.

By contrast, market capitalization is large relative to total equity of KRW 123.9 billion at the end of 2025, so the price-to-book multiple sits in a range with a large premium to net assets. The dividend yield is low, which places earnings growth rather than shareholder returns at the center of valuation.

The sum of net income attributable to controlling shareholders over the last four quarters is KRW 46 billion, and quarterly profit has declined since its fourth-quarter 2025 peak, so the reading of multiples depends heavily on whether profit holds at its current level.

Since profit has recovered from the 2023 low, the earnings-based view has more room for comparison with past multiples. Whether the multiple looks high or low depends on views about the durability of earnings and the effect of capacity expansion.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Electronic materials demand growth

Cumulative revenue for the first three quarters of 2026 rose about 42% year on year, and operating profit rose about 55%. The company said electronic materials and raw materials such as nucleosides and mPEG supported the increase.

Low-dielectric materials go into copper-clad laminates used in AI accelerators, and the company said demand continues as data center buildouts expand.

Structural margin improvement

Operating margin rose from 2.3% in 2023 to 30.1% in 2025. Operating profit reached KRW 34.3 billion in 2025, up from KRW 4.66 billion in 2024. As revenue scale grew, fixed cost burden appears to have eased, and whether this pattern holds is central to the assessment.

Planned capacity expansion

The third Ulsan plant is under construction with a target completion date at the end of January 2027. The company said it is building the plant to meet rising demand for advanced AI materials and pharmaceutical raw materials, and plans to expand production capacity once it is complete. If completion proceeds on schedule, supply capacity would step up.

09

Bear factors

Slowing quarterly profit

Net income attributable to controlling shareholders fell for three consecutive quarters, from KRW 15.7 billion in the fourth quarter of 2025 to KRW 11.7 billion in the first quarter of 2026, KRW 10.4 billion in the second quarter, and KRW 8.29 billion in the third quarter.

Third-quarter 2026 operating profit fell 9.8% from the prior quarter. Revenue rose through the second quarter of 2026 but declined 5.2% in the third quarter.

Concentration in electronic materials and cycle dependence

In the first three quarters of 2025, low-dielectric electronic materials accounted for 54% of total revenue. Because revenue depends on a specific product and AI equipment investment flows, earnings could swing widely if demand slows.

Cumulative biomedical revenue of KRW 2.6 billion in the first three quarters of 2026 is small relative to the company, so diversification effects are limited.

Multiple burden and low dividend

Market capitalization sits well above total equity of KRW 123.9 billion at the end of 2025, placing the stock in a range with a large premium to net assets. The dividend yield is low, so dividends provide limited support for the share price. While quarterly profit is declining, a shortfall against expectations could compress the multiple.

10

Risk factors

Demand cycle risk

Demand for low-dielectric materials is tied to AI accelerator and data center investment. Slower investment or inventory adjustments by customers could disrupt revenue. Because third-quarter 2026 revenue declined from the prior quarter, quarter-to-quarter volatility from demand changes needs attention.

Plant completion and utilization risk

The third Ulsan plant targets completion at the end of January 2027. Delays in completion or output below target during early operation would postpone the effect of added capacity. The timing at which investment costs flow through to earnings should also be monitored.

Biotech business performance risk

The biomedical division comprises stem cell therapies, cosmetics, CMO and contract testing. Cumulative revenue for the first three quarters of 2026 was KRW 2.6 billion, up about 39% year on year, but the scale remains small. Whether the planned CMO expansion leads to actual contract wins will determine performance in this division.

11

What to watch next

  1. End of January 2027

    This is the target completion date for the third Ulsan plant. Whether the plant is completed on time and whether expanded capacity starts operating will indicate supply capability for electronic materials and raw materials.

  2. Early 2027 (typically January to February)

    This is the expected timing of fourth-quarter and full-year 2026 results. It will show whether full-year 2026 revenue exceeds KRW 114.1 billion and whether net income attributable to controlling shareholders ends its three-quarter decline.

  3. End of March 2027

    This is the deadline for the 2026 annual report. The report will disclose full-year 2026 results and segment revenue, allowing comparison with 2025 figures.

  4. Mid-May 2027 (typically)

    This is the typical timing of first-quarter 2027 results. It will show whether early operation of the third plant is reflected in quarterly revenue and operating margin.

12

Overall view

Pharmicell expanded its scale after the 2023 low, reaching full-year 2025 revenue of KRW 114.1 billion and operating profit of KRW 34.3 billion, and its cumulative results for the first three quarters of 2026 have continued to grow by double digits year on year.

Growth centers on low-dielectric electronic materials linked to AI infrastructure demand, with pharmaceutical raw materials such as nucleosides adding to it. Positive factors include the improvement in operating margin to 30.1% in 2025 and the plan to expand capacity with the third Ulsan plant.

On the other side, net income attributable to controlling shareholders has declined for three consecutive quarters since its fourth-quarter 2025 peak, and third-quarter 2026 revenue and operating profit both fell from the prior quarter.

Because more than half of revenue depends on electronic materials, volatility tied to the demand cycle is significant, and the biomedical division is small. On valuation, market capitalization sits in a range with a large premium to net assets, and the dividend yield is low.

The next checkpoints are the completion of the third Ulsan plant at the end of January 2027, fourth-quarter and full-year 2026 results in early 2027, and the annual report by the end of March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 14 more articles and sources
  1. comp.wisereport.co.kr
  2. view.asiae.co.kr
  3. hankyung.com
  4. newstown.co.kr
  5. pharmicell.com
  6. newspim.com
  7. oreumnstar.com
  8. newspim.com
  9. newstown.co.kr
  10. edaily.co.kr
  11. dailyinvest.kr
  12. edaily.co.kr
  13. newsprime.co.kr
  14. yakup.com

Report written 2026-11-12 · Data as of 2026-11-11

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis